COVID‑19 Vaccination and Cardiovascular Events: A Systematic Review and Bayesian Multivariate Meta‑Analysis of Preventive Benefits and Risks

Raheleh Karimi, Mina Norozirad, Foad Esmaeili, Marjan Mansourian, Hamid R. Marateb

Abstract


Background: To provide a detailed understanding and apply a comprehensive strategy, this study examines the association between COVID‑19 vaccination and cardiovascular events. We conducted a Bayesian multivariate meta‑analysis using summary data across multiple outcomes including myocardial infarction, stroke, arrhythmia, and CAD, considering potential dependencies in the data. Markov chain Monte Carlo (MCMC) methods were detected for easy implementation of the Bayesian approach. Also, the sensitivity analysis of the model was done by using different priors. Methods: Fifteen studies were included in the systematic review, with eleven studies comparing the results between the vaccine group and the unvaccinated group. Additionally, six studies were used for further analysis to compare mRNA COVID‑19 Vaccines (Pfizer‑BioNTech and Moderna). Results: Bayesian meta‑analysis revealed a link between vaccines and CAD risk (OR, 1.70; 95% CrI: 1.11–2.57), particularly after BNT162b2 (OR, 1.64; 95% CrI: 1.06–2.55) and second dose (OR, 3.44; 95% CrI: 1.99–5.98). No increased risk of heart attack, arrhythmia, or stroke was observed post‑COVID‑19 vaccination. As the only noteworthy point, a protective effect on stroke (OR, 0.19; 95% CrI: 0.10–0.39) and myocardial infarction (OR, 0.003; 95% CrI: 0.001–0.006) was observed after the third dose of the vaccine. Conclusions: Secondary analysis showed no notable disparity in cardiovascular outcomes between BNT162b2 and mRNA vaccines. The association of COVID‑19 vaccination with the risk of coronary artery disease should be considered in future vaccine technologies for the next pandemic.

 

International Journal of Preventive Medicine 16():14, March 2025. | DOI: 10.4103/ijpvm.ijpvm_260_24

Corresponding Author: Dr. Marjan Mansourian

E‑mail:jmansourian@hlth.mui.ac.ir

You can also search for this author in: PubMed Google Scolar


Keywords


Arrhythmias; cardiac; coronary artery disease; COVID‑19 vaccines; myocardial infarction; SARS‑CoV‑2; stroke

Full Text:

PDF

References


WHO Coronavirus (COVID-19) Dashboard [Internet].Available from: https://covid19.who.int. [Last accessed on 2023 Nov 22.

Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Frontiers in public health. 2022;10:873596.

Ssentongo P, Ssentongo AE, Voleti N, Groff D, Sun A, Ba DM, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC infectious diseases 2022;22:439.

World Health Organization (2022) WHO COVID-19 Dashboard. https://covid19.who.int/.

Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New England Journal of Medicine 2021;385:1078-90.

Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (PfizerBioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094-9.

Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiology 2021;6:1202-6.

Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Bmj 2021;374:n1931.

Lai FTT, Chua GT, Chan EWW, Huang L, Kwan MYW, Ma T, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerging microbes & infections 2022;11:885-93.

Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. Jama 2022;328:887-9.

Ye X, Yan VK, Yiu HHE, Shami JJ, Kang W, Ma T, et al. BNT162b2 or CoronaVac Vaccinations Are Associated With a Lower Risk of Myocardial Infarction and Stroke After SARS‐ CoV‐2 Infection Among Patients With Cardiovascular Disease. Journal of the American Heart Association 2023;12:e029291.

Whiteley WN, Ip S, Cooper JA, Bolton T, Keene S, Walker V, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS medicine 2022;19:e1003926.

Wong CKH, Lau KTK, Xiong X, Au ICH, Lai FTT, Wan EYF, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS medicine 2022;19:e1004018.

Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, et al. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France. Annals of internal medicine 2022;175:1250-7.

Wan EYF, Chui CSL, Mok AHY, Xu W, Yan VKC, Lai FTT, et al. mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study. Drug Safety 2022;45:1477-90.

Ahmed SK, Mohamed MG, Essa RA, Rashad EAA, Ibrahim PK, Khdir AA, et al. Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;16:102513.

Chou OHI, Mui J, Chung CT, Radford D, Ranjithkumar S, Evbayekha E, et al. COVID-19 vaccination and carditis in children and adolescents: A systematic review and meta-analysis. Clinical Research in Cardiology 2022;111:1161-73.

Oueijan RI, Hill OR, Ahiawodzi PD, Fasinu PS, Thompson DK. Rare Heterogeneous Adverse Events Associated with mRNABased COVID-19 Vaccines: A Systematic Review. Medicines 2022;9:43.

Ling RR, Ramanathan K, Tan FL, Tai BC, Somani J, Fisher D, et al. Myopericarditis following COVID-19 vaccination and nonCOVID-19 vaccination: a systematic review and meta-analysis. The Lancet Respiratory Medicine 2022;10:679-88.

Chang Y, Lv G, Liu C, Huang E, Luo B. Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis. Expert Review of Vaccines 2023;22:25-34.

Khaity A, Abdelwahab OA, Albakri K, Diab RA, Al-Dardery NM, Abbassy M, et al. Cardiovascular disease and COVID-19 vaccines: a systematic review and analysis of published cases. European Cardiology Review 2023;18.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery 2021;88:105906.

National Heart L, Institute B. Development and use of study quality assessment tools. National Heart Lung and Blood Institute Available online at: https://wwwnhlbinihgov/healthtopics/study-quality-assessment-tools. 2016.

Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2011;2:1-12.

Nam IS, Mengersen K, Garthwaite P. Multivariate meta‐analysis. Statistics in medicine 2003;22:2309-33.

Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta‐analysis: multivariate approach and meta‐regression. Statistics in medicine 2002;21:589-624.

Wei Y, Higgins JP. Bayesian multivariate meta‐analysis with multiple outcomes. Statistics in medicine 2013;32:2911-34.

Daniels MJ, Pourahmadi M. Bayesian analysis of covariance matrices and dynamic models for longitudinal data. Biometrika 2002;89:553-66.

Schervish MJ. Theory of statistics. USA: Springer Science & Business Media; 2012. p. 4.

Wei Y, Higgins JP. Estimating within‐study covariances in multivariate meta‐analysis with multiple outcomes. Statistics in Medicine 2013;32:1191-205.

Plummer M, editor JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd international workshop on distributed statistical computing; 2003: Vienna, Austria.

Petrudi NR, Abdollahi M, Mirzaii-Dizgah I. Myocardial Infarction Following Vaccination Against COVID-19: A Systematic Review. Annals of Military and Health Sciences Research 2023;21.

Baqi DH, Kakamad FH, Mahmood ZH, Fattah FH, Ahmed SF, Hassan MN, et al. Myocardial infarction following COVID-19 vaccine administration; a systematic review. Heliyon 2022.

Stefanou MI, Palaiodimou L, de Sousa DA, Theodorou A, Bakola E, Katsaros DE, et al. Acute arterial ischemic stroke following COVID-19 vaccination: a systematic review and metaanalysis. Neurology 2022;99:e1465-e74.

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature medicine 2021;27:2144-53.

Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Bmj 2021;374.

Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. Jama 2022;327:80-2.

Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. Jama 2021;326:1390-9.

Jiang J, Chan L, Kauffman J, Narula J, Charney AW, Oh W, et al. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection. Journal of the American College of Cardiology 2023;81:928-30.

Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nature Reviews Immunology 2018;18:733-44.

Cines DB, Bussel JB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. Mass Medical Soc; 2021. p. 2254-6.

Chamling B, Vehof V, Drakos S, Weil M, Stalling P, Vahlhaus C, et al. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clinical Research in Cardiology 2021;110:1850-4.

Baronti A, Gentile F, Manetti AC, Scatena A, Pellegrini S, Pucci A, et al. Myocardial infarction following COVID-19 vaccine administration: post hoc, ergo propter hoc? Viruses 2022;14:1644.

Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle P, Eichinger S. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination. 2021.

Boivin Z, Martin J. Untimely myocardial infarction or COVID-19 vaccine side effect. Cureus 2021;13.

Kounis NG, Mazarakis A, Tsigkas G, Giannopoulos S, Goudevenos J. Kounis syndrome: a new twist on an old disease. Future Cardiology 2011;7:805-24.

Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines 2021;9:221.

Ab Rahman N, Lim MT, Lee FY, Lee SC, Ramli A, Saharudin SN, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Vaccine 2022;40:4394-402.

Flacco ME, Acuti Martellucci C, Soldato G, Di Martino G, Carota R, De Benedictis M, et al. COVID-19 vaccination did not increase the risk of potentially related serious adverse events: 18-month cohort study in an Italian province. Vaccines 2022;11:31.

Botton J, Jabagi MJ, Bertrand M, Baricault B, Drouin J, Le Vu S, et al. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France. Annals of Internal Medicine 2022;175.

Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, et al. Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study. Cell Rep Med 2023;4:101195.

Lai FTT, Chan EWW, Huang L, Cheung CL, Chui CSL, Li X, et al. Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. Journal of the American College of Cardiology 2022;80:2255-65.

Bardenheier BH, White EM, Blackman C, Gravenstein S, Gutman R, Sarkar IN, et al. Adverse events following third dose of mRNA COVID-19 vaccination among nursing home residents who received the primary series. Journal of the American Geriatrics Society 2022;70:1642-7.

Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Bmj-British Medical Journal 2021;374.

Hause AM. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged≥ 12 years—United States, August 31–October 23, 2022. MMWR Morbidity and Mortality Weekly Report 2022;71.

Sa S, Lee CW, Shim SR, Yoo H, Choi J, Kim JH, et al. The safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 vaccines: safety monitoring for adverse events using real-world data. Vaccines 2022;10:320.

Dickerman BA, Madenci AL, Gerlovin H, Kurgansky KE, Wise JK, Figueroa Muñiz MJ, et al. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. JAMA Intern Med 2022;182:739-46.